How to read peptide research comes down to a few questions. Was it done in people or animals? How many? Was there a randomized control group? What did it measure, and who paid for it? A large randomized, placebo-controlled human trial outranks any number of rat studies. Only 37% of highly cited animal findings were later confirmed in human randomized trials.[2]
This consumer guide walks through study types, how to search PubMed and ClinicalTrials.gov, and the red flags that come up again and again with peptides. It also covers how to interpret a peptide research paper section by section. New to peptides? Start at the peptide basics hub.
The evidence ladder
| Study type | What it is | How much it tells you |
|---|---|---|
| Cell (in vitro) | Peptide added to cells in a dish | Mechanism ideas only |
| Animal | Mice, rats, dogs and others | Hypotheses; often fail in people[2] |
| Case report or series | One or a few patients, no comparison | Signals, not proof |
| Observational | Compares people who chose to use something | Associations, open to bias |
| Uncontrolled pilot | Small group, everyone treated | Feasibility and early safety |
| Randomized controlled trial (RCT) | Random assignment to drug or placebo/comparator | Can show cause and effect |
| Systematic review / meta-analysis | Pools studies using a stated method | Strongest when built on RCTs |
Why animal results so often fail is covered in animal vs human peptide studies.
How to read a paper, section by section
- Title and abstract. Note the design (randomized? placebo?) and population (humans? rats?). Abstracts can oversell. In a JAMA analysis of trials with non-significant main results, 58% of abstract conclusions contained “spin,” presenting the treatment as beneficial anyway.[3]
- Methods. Look for the number of participants, how long they were followed, and the primary outcome chosen in advance. A change in primary outcome after the fact is a warning sign.
- Results. Compare against the control group, not just before and after. Check how many people dropped out.
- Absolute vs relative numbers. In SELECT, semaglutide cut major heart events by 20% in relative terms. In absolute terms, that was 6.5% versus 8.0%, a 1.5-point difference over about three years.[10] See our semaglutide profile.
- Discussion and limitations. Good papers state their weaknesses plainly.
- Funding and conflicts. A Cochrane review found industry-sponsored studies reported favorable efficacy results more often than other studies (risk ratio 1.27).[4] Funding doesn’t make a study wrong, but it is context.
Searching PubMed
PubMed is the free National Library of Medicine database of biomedical literature.
- Search the peptide name plus a topic, such as BPC-157 tendon.
- Use the Article type filters for “Randomized Controlled Trial” or “Systematic Review.”
- Use the Species: Humans filter to separate human from animal work.
- Check whether a paper has been retracted; PubMed marks retracted articles. A review of 2,047 retracted papers found 67.4% were retracted for misconduct, including fraud or suspected fraud (43.4%).[7]
Being indexed is not a mark of quality. Predatory journals publish for a fee with little or no real peer review.[8]
Reading an FDA label
For approved peptide drugs, the prescribing information is often the best single summary. It is free on DailyMed. Labels follow a standard layout. Section 1 lists approved uses, section 2 dosing, sections 5 and 6 warnings and side effects, section 12.3 pharmacokinetics (including bioavailability and half-life), and section 14 the clinical trials behind approval. Because FDA reviews this text, it is a useful check against marketing claims. Our peptide bioavailability guide pulls numbers straight from these sections. Unapproved peptides have no label at all, which is itself informative.
Using ClinicalTrials.gov
Trial registration became a condition of publication in major journals after a 2004 statement by the International Committee of Medical Journal Editors. The aim was to stop unfavorable trials from vanishing.[5]
What a listing does and doesn’t mean:
- ClinicalTrials.gov states that listing a study doesn’t mean the federal government evaluated it. Safety and scientific validity are the responsibility of the sponsor and investigators, and staff do only limited quality control.[6]
- “Recruiting” means a trial says it is enrolling. It doesn’t mean results exist.
- Check the Results tab and search PubMed for the NCT number to find published outcomes.
Fake or fictional records. In 2026 we found records for popular research peptides, including TB-500 and GHK-Cu, whose own summaries describe them as fictional example records, yet listed as recruiting. Red flags include an unfamiliar sponsor with no publications, summaries that read like templates, and contact details that don’t match the listed institution. We don’t cite such records.
A worked example: BPC-157
BPC-157 is often described online as “well studied.” A 2026 systematic review of human evidence found three small studies with 30 people in total, none with a control group. It rated certainty as very low.[9] Most of the volume behind the claim is animal research. Asking “in whom, compared with what?” changes the picture.
What’s established vs what to watch
Established: randomized human trials are the most reliable single source. Small, unblinded and animal studies frequently overstate benefits.[1][2]
Watch for: AI-generated summaries and papers, and claims that AI “designed” a product. See AI-designed peptides.
Putting it into practice
When you read a peptide claim, find the original paper, place it on the evidence ladder and check for a registered human trial with results. For research that has held up, see peptide research highlights 2026 and the most-cited peptide studies.
Questions to discuss with a clinician
- Can you help me find the original study behind this claim?
- Was it done in people like me, and how big was the effect?
- Has it been confirmed by an independent group?
- Does a registered trial have published results yet?
